WI
Windlas Biotech Ltd (WINDLAS)
₹961.25
Mkt cap
₹2,017 Cr
P/E ratio
30.20
P/B
3.48
Div yield
0.64%
ROE
12.20%
ROCE
15.90%
EPS (TTM)
₹31.83
Book value
₹276
52W range
697–1,182
Sector
Healthcare
Price history
Previous close
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics. [1]
NSE WINDLASBSE 543329
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−18.67% from high₹961
₹697+37.83% from low₹1,182
Current
₹961.25
Prev close
₹982.45
Day
−2.16%
Price performance
1D
−2.18%
1W
−4.04%
1M
+6.73%
3M
−2.75%
6M
+22.84%
1Y
+17.10%
YTD
+21.85%
Financials
Revenue, profit & margin
P/E ratio
30.2×
WINDLAS is 10% below the sector median of 33.4×
WINDLAS30.2×
Sector median33.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 | 248 | 264 | |
| YoY Sales growth | +15% | +36% | +22% | +21% | +22% | +20% | +18% | +20% | +19% | +20% | +18% | +18% | +19% | |
| Expenses | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 | 221 | 235 | |
| Operating Profit | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 | 27 | 29 | |
| OPM % | 12% | 13% | 13% | 12% | 12% | 13% | 13% | 13% | 13% | 10% | 11% | 11% | 11% | |
| Other Income | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 | 5 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Depreciation | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 | 7 | 8 | |
| Profit before tax | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 | 23 | 23 | |
| Tax % | 23% | 24% | 25% | 26% | 23% | 24% | 22% | 24% | 25% | 25% | 21% | 23% | 23% | |
| Net Profit | 14 | 15 | 17 | 13 | 16 | 15 | 16 | 18 | 18 | 15 | 16 | 18 | 18 | |
| EPS in Rs | 6.75 | 7.26 | 8.15 | 6.45 | 7.49 | 7.29 | 7.77 | 8.43 | 8.45 | 7.09 | 7.59 | 8.55 | 8.75 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202663.31%Promoter
Promoters63.31%
FIIs2.09%0.05
DIIs7.24%2.60
Public27.35%2.55
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,867.50 | 36.42 | 4,48,076 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,080.00 | 86.07 | 2,94,139 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,691.20 | 82.19 | 1,78,438 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,220.00 | 89.52 | 1,19,949 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,192.00 | 26.24 | 1,18,902 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,377.90 | 41.11 | 1,15,092 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,394.50 | 36.28 | 1,12,660 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Windlas Biotech | ₹977.20 | 30.25 | 2,017 | 0.64% | 18 | +1.40% | 264 | +18.66% | 15.90% |
| Median: 160 Co. | ₹449.50 | 33.40 | 2,018 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports6
Concall transcripts54
TranscriptNov 2026PPTNov 2026RECNov 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 13 Nov - Q2 & H1 FY27 Earnings Conference Call TranscriptRecording Of Conference Call 6 Nov - Audio recording of October 30, 2026 analyst call for Q2 and H1 FY26 uploaded on website.Announcement under Regulation 30 (LODR)-Press Release / Media Release 5 Nov - Windlas Biotech reported H1/Q2 FY27 results, crossed Rs.500 crore revenue, commercialized Plant-6, and secured EU GMP certification.Announcement under Regulation 30 (LODR)-Change in Management 5 Nov - Approved Q2/H1 FY27 results; Ashok Kumar Windlass resigned as WTD/director, Hitesh Windlass appointed chairman on Nov 5, 2026.Announcement under Regulation 30 (LODR)-Resignation of Director 5 Nov - Q2/H1 FY27 results approved; Ashok Kumar Windlass resigned as WTD; Hitesh Windlass appointed Chairman.






